20160531 - May 31, 2016
MAY 31, 2016 

University of Maryland Cancer Center Earns Comprehensive Designation

The University of Maryland Marlene and Stewart Greenebaum Cancer Center has earned the designation as an NCI-designated Comprehensive Cancer Center.

The center announced the NCI designation May 31.

On Aug. 1, when the designation goes in effect, Maryland will become one of the 46 Comprehensive Cancer Centers in the U.S.

    20160527 - May 27, 2016
    ISSUE 21 – May 27, 2016PDF



    Slamming the Door – Part XIII

    Chair of CPRIT Oversight Committee:

    “Better to Get Them All Out of the Way Now”

    What were Texas politicians and CPRIT officials thinking as they were pounded by blistering letters of resignation?

    Condemnation seemed to be rolling off their backs as they marched toward what they thought was their great triumph.

    Jimmy Mansour, chairman of CPRIT’s oversight committee, mistakenly hit Reply All, sending an especially contemptuous email to a scientist who was announcing his resignation from CPRIT. In the email that came into public view because of his sloppiness, Mansour, a telecommunications entrepreneur, belittles scientists and the peer review process.

    Conversation with The Cancer Letter

    Candace Johnson: A New Vision for Roswell Park

    Since Candace Johnson’s appointment as president and CEO of the Roswell Park Cancer Institute in February 2015, the institute has recruited 22 new faculty members and promoted 19 faculty members into senior leadership positions.

    “I’m a new leader. I have a new style, a new vision of where Roswell Park is going,” Johnson, the Wallace Family Chair in Translational Research, said to The Cancer Letter. “We have new and different challenges, and unless my entire workforce understood these challenges and embraced the changes I’ve been implementing, we wouldn’t have a chance.”

    ASCO Cervical Cancer Guideline Addresses Global Disparities

    The American Society of Clinical Oncology issued its first clinical practice guideline for invasive cervical cancer.

    The guideline provides evidence-based recommendations for four tiers based on available resources for cervical cancer screening and treatment: basic, limited, enhanced and maximal. For each setting, and for each stage of cervical cancer, the guideline recommends optimal therapy and palliative care. The guideline was published in the Journal of Global Oncology and was endorsed by the Society of Gynecologic Oncology.

    Survey: 28 Percent of Doctors See Clinical Trials as Last Resort

    Only 40 percent of Americans have a positive overall impression of clinical trials, according to a national survey conducted for Memorial Sloan Kettering Cancer Center.

    The survey, which polled over 2,100 people including nearly 600 physicians, found that 28 percent of doctors considered clinical trials as treatments of last resort.

    In Brief
    • Northwestern to host 5k coinciding with ASCO’s annual meeting in Chicago
    • The Canadian Cancer Society and Merck to collaborate on New Horizons project

    • American Skin Association presents annual awards

    • Margaret Foti honored by Ovarcome foundation

    • Seattle Children’s and Juno Therapeutics to collaborate on T-cell immunotherapies

    • Memorial Sloan Kettering and Hunter Douglas establish graduate fellowship

    • University of Chicago and Blue Cross and Blue Shield launch oncology medical home

    • Lightpoint Medical signs agreement for Beta Emission Tomography technology from University of Arizona researchers

    Drugs and Targets
    • CHMP issues positive opinion for Kyprolis in multiple myeloma

    • ProNAi Therapeutics and Carna Biosciences to commercialize AS-141

     

    20160520 - May 20, 2016
    ISSUE 20 – May 20, 2016PDF



    NCI Identifies Moonshot Priorities

    NCI is working to provide five to ten recommendations for Vice President Joe Biden’s cancer moonshot program, officials said at a recent advisory committee meeting.

    At a meeting of the Frederick National Laboratory Advisory Committee May 11, top NCI officials described the mechanisms that will be used to provide recommendations for spending new money that may be directed at cancer research.

    The institute’s Blue Ribbon Panel—consisting of 28 members representing academia, government, industry and patient advocates—has assembled seven working groups.

    Guest Editorial

    Nancy Davidson: Capturing the Moonshot’s Momentum

    Vice President Joe Biden’s National Cancer Moonshot Initiative has touched off an unprecedented national and international dialogue about cancer.

    My presidential year at the American Association for Cancer Research brings the special opportunity to ensure that this momentum is captured and fully utilized to position cancer research as the key to saving more lives from cancer.

    The AACR has been and continues to be a trusted adviser to the vice president on this important initiative.

    Capitol Hill

    House Committee Provides Forum for Opponents of Part B Payment Model

    A Congressional committee earlier this week provided a venue for opponents of a controversial Medicare Part B payment model to argue against its implementation by Centers for Medicaid Services.

    Witnesses at the May 17 hearing of the health subcommittee of the House Committee on Energy and Commerce said the payment model would make it difficult for Medicare patients to obtain care, and one witness likened the model to an unethical clinical trial. Also, in what couldn’t be a coincidence, two witnesses—representing patients with immune deficiencies and rheumatology—submitted written testimony that contained identical paragraphs.

    In Brief
    • James Brink elected chair of American College of Radiology
    • Michael Kaplan named president and CEO of Melanoma Research Alliance

    • Hong-yu Li named Arkansas Research Alliance Scholar and endowed chair

    • CPRIT awards 35 grants totaling $79.2 million

    • Senate marks up FDA tobacco regulation appropriations

    Drugs and Targets
    • FDA grants accelerated approvals to Tecentriq and Opdivo

    • FDA warns doctors about counterfeit BiCNU